What is Pulmocide?
Pulmocide is a specialized biopharmaceutical enterprise dedicated to the discovery and development of innovative treatments for respiratory tract infections. The company addresses a significant unmet medical need by targeting conditions that cause severe complications and diminish patient quality of life. By leveraging a deep understanding of respiratory pathology, Pulmocide has built a robust portfolio of therapeutic candidates designed to combat both acute and chronic infections. Its market position is defined by a commitment to scientific excellence and a strategic focus on high-impact, life-saving interventions, making it a key contributor to the evolving landscape of modern pulmonary care.
How much funding has Pulmocide raised?
Pulmocide has raised a total of $149.9M across 3 funding rounds:
Series A
$27.5M
Series B
$30.4M
Series C
$92M
Series A (2013): $27.5M with participation from F-Prime Capital Partners, Imperial Innovations Group plc, Johnson & Johnson Development Corporation, and S.V. Life Sciences
Series B (2017): $30.4M led by JJDC, Inc, S.V. Life Sciences, S.R. One, Touchstone Innovations plc, F-Prime Capital, and Longwood Fund
Series C (2021): $92M supported by SV Health Investors, Jeito Capital, Asahi Kasei Pharma, Adjuvant Capital, and SR One
Key Investors in Pulmocide
SV Health Investors
A specialist investment firm backing innovative health care and life science companies, partnering with founders to provide capital and sector expertise from early growth through scale.
SR One
A transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies, leveraging deep sector expertise to translate innovative technologies into new medicines.
F-Prime Capital
A global venture capital firm with a team of investors, engineers, and scientists dedicated to investing in healthcare and technology to drive meaningful medical advancements.
What's next for Pulmocide?
With the successful closure of its latest financing round, Pulmocide is well-positioned to advance its lead programs through critical clinical trial phases. The strategic deployment of these funds will likely prioritize the expansion of its research and development infrastructure, alongside the strengthening of its intellectual property portfolio. Looking ahead, the company is expected to focus on optimizing its clinical trial designs and exploring potential partnerships that could enhance its commercial reach. By maintaining its focus on high-impact respiratory therapeutics, Pulmocide is poised to address the growing global demand for effective treatments, potentially setting new standards for care in the biopharmaceutical industry.
See full Pulmocide company page
